BC Extra | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

Ahead of NDA submission, Zealand raising cash  Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) is raising DKK559.6 million ($82.4 million) via a private placement and directed share issue to existing investor Van Herk Investments. Zealand will sell...
BC Extra | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

BrightGene advances toward STAR market   The Shanghai Stock Exchange approved an application from BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) to raise RMB360 million ($50.3 million) in a listing on its STAR market. If...
BC Extra | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes...
BC Week In Review | Dec 15, 2017
Financial News

Bellus Health raises C$20M in follow-on

On Dec. 12, Bellus Health Inc. (TSX:BLU) raised C$20 million ($15.6 million) through the sale of 52.6 million shares at C$0.38 in a follow-on. The price values the company at C$45.4 million ($35.4 million). Bloom...
BC Week In Review | Jun 13, 2016
Company News

Afferent, Merck deal

Merck will acquire Afferent for $500 million in cash and up to $750 million in clinical and commercialization milestones for candidates in Afferent’s pipeline, including AF-219 . AF-219, a purinergic receptor P2X ligand-gated ion channel 3...
BC Extra | Jun 10, 2016
Top Story

Merck acquiring Afferent

Merck & Co. Inc. (NYSE:MRK) is acquiring Afferent Pharmaceuticals Inc. (San Mateo, Calif.) for $500 million in cash. The deal gives the pharma Afferent's chronic cough candidate AF-219 , a purinergic receptor P2X ligand-gated ion channel...
BC Week In Review | Jan 18, 2016
Clinical News

AF-130: Phase I started

Afferent began a 2-part, double-blind, placebo-controlled, U.K. Phase I trial to evaluate oral AF-130 in about 109 healthy volunteers. The first part will evaluate single ascending doses of AF-130 in about 64 healthy volunteers. The...
BC Week In Review | Dec 7, 2015
Clinical News

AF-219: Phase II started

Afferent began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 50 mg oral AF-219 twice daily in a 2-way crossover consisting of 14-day periods in about 50 patients. Afferent has exclusive, worldwide rights to...
BC Extra | Jul 9, 2015
Financial News

Afferent taps crossover funds for $55M series C

Afferent Pharmaceuticals Inc. (Boston, Mass.) raised $55 million in a series C round led by new investor Fidelity. New investors Jennison Associates; New Leaf Venture Partners; Partner Fund Management; Redmile Group; Tekla Healthcare Investors; Tekla...
BC Week In Review | Mar 9, 2015
Clinical News

AF-219: Phase II data

Afferent reported data from a double-blind, U.S. Phase II trial in 74 female patients with moderate to severe symptoms of IC/BPS showing that there was a “positive trend” for improving NPRS scores in patients who...
Items per page:
1 - 10 of 35